This inventor holds 1 USPTO granted patent and 9 published patent applications and 1 EPO patent. Top assignee: Societe Des Produits Nestle S.a.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Matthew Sanders - Innovator in AMPK Activation Compounds
Introduction
Matthew Sanders is a notable inventor based in Epalinges, Switzerland. He has made significant contributions to the field of cardiometabolic health through his innovative research and development of compounds that activate AMPK. His work is particularly relevant in addressing conditions such as obesity, type 2 diabetes, and cardiovascular diseases.
Latest Patents
Matthew Sanders holds a patent for a direct AMPK activator compound. The patent describes a compound with a general formula I that is utilized for the activation of AMPK. The specific compounds include 9,10 dihydrophenanthrenes, particularly those selected from the group consisting of: (i) Lusianthridin, which is 7-Methoxy-9,10-dihydrophenanthrene-2,5-diol, (ii) 7-Methoxy-9,10-dihydrophenanthrene-2,3,5-triol, (iii) 9,10-dihydrophenanthrene-2,5-diol, (iv) 9,10-Dihydrophenanthrene-2,4,7-triol, and (v) 9,10-Dihydro-7-methoxy-3,5-phenanthrenediol. The activation of AMPK is crucial for improving conditions related to cardiometabolic health, obesity, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, and cancer.
Career Highlights
Matthew Sanders is currently employed at Société des Produits Nestlé S.A., where he continues to innovate and develop new solutions in the health sector. His work has garnered attention for its potential impact on improving health outcomes for various diseases.
Collaborations
Matthew collaborates with esteemed colleagues such as Denis Marcel Barron and Yann Ratinaud. Their combined expertise contributes to the advancement of research in AMPK activation and its applications in health.
Conclusion
Matthew Sanders is a pioneering inventor whose work in AMPK activator compounds holds promise for addressing significant health challenges. His contributions to the field are vital for the ongoing research and development of effective treatments for cardiometabolic disorders.